Cancer Treatments & Biomarkers
Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.
Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.
Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.
Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.
Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.
Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.
Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.
Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.
Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.
Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.
Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.
Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.
A chemosensitizer is a drug that makes tumor cells more sensitive to the effects of chemotherapy. Discover the latest research on chemosensitizers here.
Drug resistance to cancer treatments is a major concern for patients with the disease. Single and multi-drug resistance to cancer therapeutics can occur, making it difficult to kill the cancer cells. Here is the latest research on drug resistance in cancer.
Drug-induced diseases (DID) also called as iatrogenic diseases. Most of these DIDs are largely preventable, if strict vigilance and proper periodic clinical and diagnostic monitoring are undertaken
Several studies have reported the role of exosomes as important mediators of angiogenesis, metastasis, and immune modulation. Exosomes also have the potential to be used as biomarkers for clinical predictions. Here is the latest research on exosomes and the tumor microenvironment.
FMS related tyrosine kinase 3 (FLT3) is a frequently mutated receptor tyrosine kinase in Acute Myeloid Leukemia. Novel Tyrosine kinase inhibitors against FLT3 are currently in clinical trial. Discover the latest research on FLT3 Inhibitors in Acute Myeloid Leukemia here.
Genome editing technologies enable the editing of genes to create or correct mutations or express genes of interest. Here is the latest research on genome editing in T- cells and their application in human diseases such as adoptive T-cell immunotherapy for cancer.
Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.
Treatment of metastatic cancers depends on the type of cancer and the severity of the disease. The regime often includes medications such as chemotherapy or hormone therapy, but may also include immunotherapy, radiation therapy, surgery or a combination. Discover the latest research on metastatic cancer treatments here.
The human microbiome has been implicated in altering cancer susceptibility and therapeutic responses to anti-cancer agents. Here is the latest research on the influence of the microbiome and cancer.
Nanoparticles are microscopic particles that are less than 100 nanometers in diameter and have a variety of uses in biomedicine including drug delivery, tumor imaging, gene delivery, etc. Here is the latest research on nanoparticles in cancer treatment.
Organoids are 3D organ-like structures that can be derived from patient tumor cells to model disease. Discover the latest research here.
Personalized cancer medicine include studying a person's genetic makeup and tumor growth to prevent, diagnose and/or treat disease. Here is the latest research on personalized cancer medicine.
Pharmacogenomics studies how medicine interacts with inherited genes. Here is the latest research on pharmacogenomics in cancer.
Photodynamic Therapy (PDT) is a minimally invasive therapeutic modality that utilizes light to activate photosensitizing compounds to kill cancer cells. Discover the latest research here.
Precision oncology is a new approach to cancer treatment, which utilizes the molecular profiling of each tumor to develop and tailor treatment strategies to each patient. The use of these biomarkers from tumors will help to predict those who will respond to specific treatments. Here is the latest research on precision oncology.
Localization of proteins is critical for ensuring the correct location for physiological functioning. If an error occurs, diseases such as cardiovascular, neurodegenerative disorders and cancers can present. Therapies are being explored to target this mislocalization. Here is the latest research on protein localization in disease and therapy.
A radiosensitizer is an agent that makes tumor cells more sensitive to radiation therapy. It is sometimes also known as a radiation sensitizer or radio-enhancer. Discover the latest research on radiosensitizers here.
Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.
Single-cell technologies are used to help scientists profile gene and protein expression levels in a variety of diseases including cancer. Here is the latest research on single-cell tumor analysis.
The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to cancer. Discover the latest research on synthetic lethality and cancer therapy here.
Anaplastic Lymphoma Kinase (ALK) is an oncogene frequently found as a fusions in non-small cell lung cancer (NSCLC), as EML4-ALK. Precision medicine uses therapeutic agents that target specific mutations, such as those found in ALK-positive NSCLC patients. Discover the latest research on Targeting ALK here.
This feed focuses on Viral Oncology Therapies, which exploits the ability of genetically engineered viruses to infect and kill cancer cells. Discover the latest research on Viral Oncology Therapies here.
Cell therapies derived from induced Pluripotent Stem Cell (iPSC) technology is emerging in cancer therapeutics. For example, iPSCs allow the development of immune therapies and drug screening programs in the genetic background of the patient. Discover the latest research on iPSC derived cell therapies for cancer here.